Evidence map›Paper›PMID 37376437›Full record

ArticleVaccines2023

Chemokine Levels among Patients with Middle East Respiratory Syndrome Coronavirus Infection.

Abdulkarim Alhetheel, Ahmed Albarrag, Zahid Shakoor, Ali Somily, Mazin Barry, Haifa Altalhi, Muhammed Bakhrebah, Majed Nassar, Mohamed Alfageeh, Ayed Assiri and 2 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Abdulkarim AlhetheelKing Saud University Medical City, Riyadh 11362, Saudi Arabia.ORCID 0000-0001-9257-1385
Ahmed AlbarragKing Saud University Medical City, Riyadh 11362, Saudi Arabia.
Zahid ShakoorKing Saud University Medical City, Riyadh 11362, Saudi Arabia.
Ali SomilyKing Saud University Medical City, Riyadh 11362, Saudi Arabia.
Mazin BarryKing Saud University Medical City, Riyadh 11362, Saudi Arabia.ORCID 0000-0003-2274-007X
Haifa AltalhiKing Saud University Medical City, Riyadh 11362, Saudi Arabia.
Muhammed BakhrebahAdvanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology, Riyadh 11442, Saudi Arabia.ORCID 0000-0002-2284-3979
Majed NassarAdvanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology, Riyadh 11442, Saudi Arabia.ORCID 0000-0003-4939-922X
Mohamed AlfageehAdvanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology, Riyadh 11442, Saudi Arabia.
Ayed AssiriCritical Care Unit, Prince Mohammed Bin Abdulaziz Hospital, Ministry of Health, Riyadh 11553, Saudi Arabia.
Sarah AlfarajCorona Center, Prince Mohammed Bin Abdulaziz Hospital, Ministry of Health, Riyadh 11553, Saudi Arabia.
Ziad MemishResearch and Innovation Center, King Saud Medical City, Ministry of Health, Riyadh 11553, Saudi Arabia.ORCID 0000-0002-5099-0714
King Saud Medical City · SAKing Abdulaziz City for Science and Technology · SAPrince Mohammed bin Abdulaziz Hospital · SAAlfaisal University · SAUniversity of Ottawa · CA

Funding

King Abdulaziz City for Science and Technology 1-02
6 · The paper itself

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant morbidity and mortality due to intense pulmonary inflammation. Enhanced chemokine-mediated leukocyte infiltration in lungs has been linked with unfavorable outcomes with respect to the disease. This cross-sectional study assessed the levels of chemokines among 46 MERS-CoV-infected patients (19 asymptomatic and 27 symptomatic) and 52 healthy controls using a customized Luminex human chemokine magnetic multiplex panel. The plasma levels of interferon-inducible protein (IP)-10 (568.5 ± 114.7 vs. 55.19 ± 5.85 pg/mL;

Indexed as

chemokinesMERS-CoVSaudi Arabia

Identifiers

PMID37376437
PMCPMC10304594
OpenAlexW4379056874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.